News & Features -
AABB 2014 Philadelphia
(Sep 16) More
Cerus and Biomedica Foscama Group S.p.A. Enter Distribution Agreement for the INTERCEPT Blood System in Italy
(Sep 11) More
Cerus Submits IDE Supplement to Make INTERCEPT Platelets Available Pre-Approval in U.S. Areas at Risk from Outbreaks of Chikungunya and Dengue
(Sep 10) More
A Single Pathogen Inactivation System for Both Platelets and Plasma
The INTERCEPT Blood System™ is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It is the first system available to treat both platelets and plasma, and simplifies processing by utilizing the same illumination device, process and active compound. This synergistic approach is designed to meet blood center requirements for efficiency, performance and compatibility with both whole blood and apheresis collections. More
INTERCEPT eNews delivers product news & information updates right to your inbox.
This site is intended for use by healthcare professionals outside of the United States only. If you are a US resident, please see important information HERE.
The INTERCEPT Blood Systems for platelets and plasma are CE marked and produced to ISO 13485 Quality Standard.